Cirius Therapeutics Expands Board of Directors with Appointment of Elaine D. Sun

SAN DIEGO and KALAMAZOO, Mich., Dec. 13, 2018 /PRNewswire/ -- Cirius Therapeutics, a clinical-stage pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and metabolic diseases, announced today that Elaine D. Sun, M.B.A., has been appointed to the company's board of directors as an independent director.

"Elaine's stellar track record as a strategic financial and business advisor in the life sciences industry further strengthens our board and leadership team," said Bob Baltera, chief executive officer of Cirius. "We expect Elaine's experience will be invaluable as we embark upon the next phase of the company's growth."

Ms. Sun, currently the chief financial officer at SutroVax, brings more than two decades of experience in the life sciences and investment banking industry. Prior to her role at SutroVax, she served as managing director and head of west coast health care for Evercore Partners, a leading independent investment banking firm, where she led biotechnology coverage. Prior to Evercore, Ms. Sun was a managing director at Merrill Lynch and Co. Ms. Sun received a B.A. in economics and Japanese studies from Wellesley College and an M.B.A. from Harvard Business School.

"NASH is a serious disease affecting millions of people and I look forward to working with the board and management team at Cirius as we continue to advance our lead program, MSDC-0602K, in order to help these patients in need," said Ms. Sun.

Cirius Therapeutics previously reported positive results for MSDC-0602K in an interim analysis of a Phase 2b clinical trial in NASH patients with fibrosis.

About Cirius Therapeutics

Cirius is a clinical-stage pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and metabolic diseases. Our lead product candidate, MSDC-0602K, is a novel small molecule being developed as a once-daily oral therapy to treat NASH with fibrosis. MSDC-0602K is designed to selectively modulate the mitochondrial pyruvate carrier (MPC), which mediates at the cellular level the effects of overnutrition, a major cause of NASH and other metabolic disorders. We are conducting a Phase 2b clinical trial of MSDC-0602K, which we have fully enrolled with 402 patients diagnosed with NASH with fibrosis.

For more information about Cirius Therapeutics, visit www.ciriustx.com.

SOURCE Cirius Therapeutics